Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash & Equivalents: 2021-2024

Historic Cash & Equivalents for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $183.6 million.

  • Kiniksa Pharmaceuticals International's Cash & Equivalents rose 57.34% to $352.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.1 million, marking a year-over-year increase of 57.34%. This contributed to the annual value of $183.6 million for FY2024, which is 70.05% up from last year.
  • Kiniksa Pharmaceuticals International's Cash & Equivalents amounted to $183.6 million in FY2024, which was up 70.05% from $108.0 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Cash & Equivalents registered a high of $183.6 million during FY2024, and its lowest value of $108.0 million during FY2023.
  • Its 3-year average for Cash & Equivalents is $138.1 million, with a median of $122.7 million in 2022.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first decreased by 12.03% in 2023, then soared by 70.05% in 2024.
  • Kiniksa Pharmaceuticals International's Cash & Equivalents (Yearly) stood at $122.5 million in 2021, then increased by 0.20% to $122.7 million in 2022, then fell by 12.03% to $108.0 million in 2023, then surged by 70.05% to $183.6 million in 2024.